Name	Keerang Park
Current Position	CdmoGen Co., Ltd., CEO
Country	Republic of Korea
Major Field	Gene Therapy

Educational Background

1975. 03 – 1978. 02 Sang Myung Girls High School, Korea
1978. 03 – 1982. 02 Seoul National University, Dept. of Food Science and Eng., B.S.
1987. 01 – 1991. 12 Purdue University (USA), Dept. of Biochemistry, Ph.D.

Professional Experience

1991. 12 – 1993. 05 Purdue University (USA), Dept. of Biochemistry, Post Doc.
1993. 07 – 2000. 10 University of Rochester (USA), School of Medicine and Dentistry, Research Assistant Professor
2002. 03 – 2021. 02 Chungbuk Health and Science University, Dept. of Biopharmacy, Professor / Gene Therapy R&D Center, Director
2007. 12 – Present Korean Society of Gene and Cell Therapy (KSGCT), 7th President and Board Members
2008. 12 – Present International Society for Pharmaceutical Engineering (ISPE), Korea Affiliate, Vice President

Other Experience and Professional Memberships

Awards Chung Cheong Buk Do Governor, Minister of Ministry of Health and Welfare, Minister of Ministry of SMEs and Startups and etc.
Professional Memberships ISPE, KSGCT, ESGCT, ASGCT, CARM, KPBMA and etc.
Certificates GMP Compliance of a Manufacturer, ISO17025, Certificate of Inno-Biz, Certificate of Venture Enterprise, Certificate of SME and etc.

Main Scientific Publications

1. "2014 Roadmap for Top Leading Biopharmaceutical Korean Industry: Strategy to Establish Top Leading Biopharmaceutical Outsourcing Infra-Structures in Korea."

Ministry of Food and Drug Safety (MFDS, KFDA) (2014).

2. "KFDA Guideline: Consideration for Non-clinical Study of Biodistribution and Analytical Method Validation using a Quantitative PCR." *Ministry of Food and Drug Safety (MFDS, KFDA)* (October 2010).

3. "KFDA Point to Consider: Consideration for QC Testing and Analytical Method Validati Gene Therapeutic Producing Cell Substrates." *Ministry of Food and Drug Safety (MFDS, K* (October 2014).

4. "KFDA Point to Consider: Gene Therapeutic Drug Development and Regulation Trends." *Ministry of Food and Drug Safety (MFDS, KFDA)* (December 2015).

5. "KFDA Point to Consider: CAR-T and Immune Cell Based Gene Therapeutic Drug Development and Regulation Trends." *Ministry of Food and Drug Safety (MFDS, KFDA)* (June 2016).

6. "KFDA Point to Consider: Current Status and Trends of Gene Therapeutic Drug Development Clinical Study." *Ministry of Food and Drug Safety* (June 2016).

7. "KFDA Point to Consider: Consideration for Non-Clinical Study and QC Testing of Adeno-Associated Virus Vector Based Gene Therapeutic Products." *Ministry of Food and Drug Safety (MFDS, KFDA)* (October 2017).

8. "KFDA Point to Consider: Consideration for QC Testing and Analytical Method Validation of Oncolytic Virus Vector Based Gene Therapeutic Products." *Ministry of Food and Drug Safety (MFDS, KFDA)* (December 2018).

9. "KFDA Point to Consider: Current Status and Trends of Gene Therapeutic Drug Development and Regulation." *Ministry of Food and Drug Safety (MFDS, KFDA)* (December 2018).

10. "Adeno-associated viral vector-mediated mTOR inhibition by short-hairpin RNA efficiently suppress laser-induced choroidal neovascularization." *Molecular Gene Therapy - Nucleic Acids* 8: 26-35 (September 2017).

11. "Intravitreal Injection of AAV Expressing Soluble VEGF Receptor-s Variant Induces Anti-VEGF Activity and Suppresses Choroidal Neovascularization." *Investigative Ophthalmology & Visual Science (IOVS)* 59(13): 5398-5407 (November 2018).

12. "Effects of stuffer DNA on the suppression of choroidal neovascularization by a rAAV expressing a mTOR-inhibiting shRNA." *Molecular Gene Therapy - Methods & Clinical Development* 14: 171-179 (September 2019) and more publications